Section Arrow
GANX.NASDAQ
- Gain Therapeutics
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 1.94
+0.05 (+2.65%)
Bid
1.9
Ask
1.95
High 1.942 
Low 1.8559 
Volume 7.66K 
Regular Hours (Closed)
Last
 1.89
+0.02 (+1.07%)
Day High 
1.995 
Prev. Close
1.87 
1-M High
2.7 
Volume 
640.92K 
Bid
1.9
Ask
1.95
Day Low
1.85 
Open
1.89 
1-M Low
1.72 
Market Cap 
79.45M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.86 
20-SMA 1.95 
50-SMA 2.11 
52-W High 4.34 
52-W Low 1.41 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.61/-0.64
Enterprise Value
79.96M
Balance Sheet
Book Value Per Share
0.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.19 -0.09 -3.95%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8558 -0.0542 -5.96%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.9001 -0.0499 -2.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.